ALLMedicine™ Psoriasis Center

Feb 6th, 2023 - Among adults with psoriatic arthritis (PsA), 11. 8% required at least one musculoskeletal surgery related to their disease, based on data from more than 1,500 individuals at the University of Toronto’s Psoriatic Arthritis Clinic.

Feb 5th, 2023 - Methotrexate (MTX) use has been suspected of increasing the risk of skin cancer. The aim of this investigation was to examine the association between the use of MTX and the risk of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSC...

Feb 4th, 2023 - MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression. Specific intra- and extracellular miRNA signatures have been identified in various diseases. Whether certain miRNA signatures are associated with psoriasis (PsO) and psoria...

Feb 4th, 2023 - This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor. This retrospective cohort study used Optum Clinformatics® Data Mart...

Feb 3rd, 2023 - The purpose of this study was to demonstrate superior efficacy of secukinumab versus placebo at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years with severe chronic plaq...

Nov 10th, 2022 - Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients...

Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Jan 11th, 2021 - To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical ca...

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Feb 3rd, 2023 - The purpose of this study was to demonstrate superior efficacy of secukinumab versus placebo at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years with severe chronic plaq...

Feb 3rd, 2023 - Guselkumab (Tremfya®), an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Given the potential role of IL-23 in the pathogenesis of guttate psoriasis, guselkumab may be an effective option to treat the initial man...

Feb 3rd, 2023 - The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.

Feb 2nd, 2023 - AVT04 is a fully human immunoglobulin class G1κ monoclonal antibody that specifically binds to the shared p40 protein subunit of IL-12 and IL-23 and therefore inhibits their activites AVT04 is being developed to be a biosimilar with the European U...

Feb 2nd, 2023 - The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (6 years to 17 years of age at the time of inclusion) with moderate to severe plaque psoriasis, through monitoring for the following adverse even...

Feb 6th, 2023 - Among adults with psoriatic arthritis (PsA), 11. 8% required at least one musculoskeletal surgery related to their disease, based on data from more than 1,500 individuals at the University of Toronto’s Psoriatic Arthritis Clinic.

Feb 2nd, 2023 - Inhibition of the PCSK9 pathway, best known for its links with dyslipidemia, had a significant association with a reduced risk of psoriasis, irrespective of lipid levels, according to a study focused on genetic variants. Genetically proxied inhibi...

Jan 31st, 2023 - To the Editor: Generalized pustular psoriasis (GPP) is a rare but severe subtype of psoriasis that can present with systemic symptoms and organ failure, sometimes leading to hospitalization and even death. 1,2 Due to the rarity of this subtype and.

Jan 31st, 2023 - To the Editor: Because the SARS-CoV-2 virus is constantly changing, routine vaccination to prevent COVID-19 infection is recommended. The messenger RNA (mRNA) vaccines from Pfizer-BioNTech and Moderna as well as the Ad26.

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.